IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

RTTNews | 975 dias atrás
IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

(RTTNews) - Oncology company IDEAYA Biosciences, Inc. (IDYA) announced that Darrin Beaupre has joined the company as its Chief Medical Officer, effective November 21, 2022.

Beaupre's extensive career includes various clinical development and translational research roles in industry, including most recently at BioSplice Therapeutics as Chief Medical Officer and Head of Research and Development in Oncology.

Beaupre previously served as Senior Vice President, Head of Early Oncology Development and Clinical Research at Pfizer, Inc., where he led cross-disciplinary groups including clinical development, clinical pharmacology, translational oncology and clinical operations related study clinicians.

Beaupre also served at Pharmacyclics (Abbvie) as Vice President, Head of Early Development and Immunotherapy, and at Amgen as Medical Director.

He was previously an Assistant Professor at the H. Lee Moffitt Cancer Center and Research Institute, and also held various earlier appointments at the University of Miami and the M.D. Anderson Cancer Center.

Marcadores : IDYA
read more
IDEAYA Biosciences Q4 Results Misses Estimates

IDEAYA Biosciences Q4 Results Misses Estimates

IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced net loss of $32.64 million or $0.52 per share, wider than $23.07 million or $0.50 per share in the prior-year quarter.
RTTNews | 526 dias atrás
IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

Oncology company IDEAYA Biosciences, Inc. (IDYA) announced Monday the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101 (IDE705) for the treatment of patients having tumors with BRCA or other homologous recombination (HR) mutations or homologous recombination deficiency (HRD).
RTTNews | 709 dias atrás
Fed Leaves Interest Rates Unchanged In Divided Decision

Fed Leaves Interest Rates Unchanged In Divided Decision

The Federal Reserve on Wednesday announced its widely expected decision to leave interest rates unchanged for the fifth consecutive meeting. In support of its dual goals of maximum employment and inflation at the rate of 2 percent over the longer run, the Fed said it decided to maintain the target range for the federal funds rate at 4.25 to 4.50 percent.
RTTNews | 2h 30min atrás
Swiss Market Settles Lower After Choppy Session

Swiss Market Settles Lower After Choppy Session

The Switzerland market ended on a weak note on Wednesday despite spending much of the day's trading session in positive territory. The focus was on corporate earnings and the developments on the trade front.
RTTNews | 2h 55min atrás
U.S. Pending Home Sales Unexpectedly Decrease In June

U.S. Pending Home Sales Unexpectedly Decrease In June

Pending home sales in the U.S. unexpectedly decreased in the month of June, according to a report released by the National Association of Realtors on Wednesday. NAR said its pending home sales index slid by 0.8 percent to 72.0 in June after jumping by 1.8 percent to 72.6 in May. Economists had expected pending home sales to rise by 0.2 percent.
RTTNews | 5h 56min atrás
Bank Of Canada Leaves Interest Rates Unchanged For Third Straight Meeting

Bank Of Canada Leaves Interest Rates Unchanged For Third Straight Meeting

In a widely expected move, the Bank of Canada on Wednesday announced that it has once again decided to leave interest rates unchanged. The Bank of Canada said it decided to maintain its target for the overnight rate at 2.75 percent, with the Bank Rate at 3 percent and the deposit rate at 2.70 percent.
RTTNews | 6h 40min atrás